BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen YC, Li CY, Tsai SJ, Chen YC. Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals. World J Clin Cases 2019; 7(11): 1270-1281 [PMID: 31236391 DOI: 10.12998/wjcc.v7.i11.1270] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Yen HH, Su PY, Liu IL, Zeng YY, Huang SP, Hsu YC, Yang CW, Chen YY. Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ 2021;9:e10944. [PMID: 33777520 DOI: 10.7717/peerj.10944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Tung CH, Li CY, Chen YC, Chen YC. Association between nucleos(t)ide analogue therapy for hepatitis B and Sjögren's syndrome: 15-year analysis of the national database of Taiwan. J Viral Hepat 2021;28:809-16. [PMID: 33550705 DOI: 10.1111/jvh.13481] [Reference Citation Analysis]
3 Su PY, Chen YY, Lai JH, Chen HM, Yao CT, Liu IL, Zeng YH, Huang SP, Hsu YC, Wu SS, Siao FY, Yen HH. Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study. J Clin Med 2021;10:5236. [PMID: 34830518 DOI: 10.3390/jcm10225236] [Reference Citation Analysis]
4 Yen HH, Su PY, Zeng YH, Liu IL, Huang SP, Hsu YC, Chen YY, Yang CW, Wu SS, Chou KC. Glecaprevir-pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting. PLoS One 2020;15:e0237582. [PMID: 32790715 DOI: 10.1371/journal.pone.0237582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chang R, Chen ML, Lin CL, Hung YM, Wei JC. Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan. JAMA Netw Open 2020;3:e2022107. [PMID: 33090225 DOI: 10.1001/jamanetworkopen.2020.22107] [Reference Citation Analysis]
6 Rossato G, Tovo CV, Almeida PRL. Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-basead regimes. Braz J Infect Dis 2020;24:25-9. [PMID: 31760038 DOI: 10.1016/j.bjid.2019.10.011] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrología (English Edition) 2021;41:578-89. [DOI: 10.1016/j.nefroe.2021.11.011] [Reference Citation Analysis]
8 Fabrizi F, Cerutti R, Dixit V, Ridruejo E. Sofosbuvir-based regimens for HCV in stage 4-stage 5 chronic kidney disease. A systematic review with meta-analysis. Nefrologia 2021:S0211-6995(21)00091-6. [PMID: 34154846 DOI: 10.1016/j.nefro.2021.01.008] [Reference Citation Analysis]
9 Yen H, Chen Y, Lai J, Chen H, Yao C, Huang S, Liu I, Zeng Y, Yang F, Siao F, Chen M, Su P. Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis. JCM 2022;11:1853. [DOI: 10.3390/jcm11071853] [Reference Citation Analysis]